
    
      This is a prospective, single arm study. To evaluate the safety and efficacy of sequential
      radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological
      malignancies with extramedullary lesions. The main endpoints were dose limiting toxicity
      (DLT) and incidence of adverse events (TEAEs).
    
  